X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9788) 9788
Book Review (1751) 1751
Publication (832) 832
Newsletter (94) 94
Book Chapter (29) 29
Magazine Article (18) 18
Conference Proceeding (17) 17
Book / eBook (8) 8
Dissertation (2) 2
Paper (2) 2
Trade Publication Article (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (8721) 8721
humans (8185) 8185
male (4685) 4685
pyrimidines - therapeutic use (4173) 4173
female (4119) 4119
pyrimidines - adverse effects (3690) 3690
middle aged (3311) 3311
adult (2832) 2832
aged (2412) 2412
imatinib mesylate (2265) 2265
pyrimidines - administration & dosage (2209) 2209
animals (2079) 2079
oncology (2072) 2072
treatment outcome (1818) 1818
benzamides (1800) 1800
pyrimidines - pharmacology (1652) 1652
pharmacology & pharmacy (1599) 1599
piperazines - therapeutic use (1401) 1401
antineoplastic agents - therapeutic use (1397) 1397
piperazines - adverse effects (1259) 1259
antineoplastic agents - adverse effects (1219) 1219
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (1190) 1190
hematology (1160) 1160
pyrimidines (1095) 1095
cancer (1085) 1085
protein kinase inhibitors - therapeutic use (927) 927
care and treatment (924) 924
abridged index medicus (905) 905
drug therapy (889) 889
dose-response relationship, drug (877) 877
therapy (840) 840
adolescent (834) 834
imatinib (834) 834
analysis (812) 812
pyrimidines - pharmacokinetics (808) 808
mice (802) 802
research (802) 802
aged, 80 and over (784) 784
sulfonamides - therapeutic use (777) 777
protein kinase inhibitors - adverse effects (767) 767
voriconazole (747) 747
rosuvastatin calcium (741) 741
young adult (733) 733
chronic myelogenous leukemia (689) 689
medicine & public health (678) 678
chronic myeloid-leukemia (643) 643
piperazines - administration & dosage (633) 633
protein-tyrosine kinases - antagonists & inhibitors (625) 625
sulfonamides - adverse effects (611) 611
rats (591) 591
safety (566) 566
pharmacokinetics (565) 565
antineoplastic agents - administration & dosage (562) 562
efficacy (551) 551
dasatinib (550) 550
chemotherapy (543) 543
time factors (542) 542
chronic myeloid leukemia (535) 535
health aspects (523) 523
ultraviolet rays - adverse effects (521) 521
double-blind method (520) 520
biochemistry & molecular biology (512) 512
risk factors (508) 508
clinical trials (503) 503
leukemia (493) 493
administration, oral (476) 476
clinical trials as topic (473) 473
medicine, general & internal (467) 467
triazoles - therapeutic use (467) 467
drug administration schedule (457) 457
antineoplastic combined chemotherapy protocols - therapeutic use (456) 456
article (452) 452
antineoplastic agents (436) 436
antifungal agents - therapeutic use (435) 435
fluorobenzenes - therapeutic use (435) 435
dna damage (422) 422
mutation (421) 421
pyrroles - therapeutic use (419) 419
sulfonamides - administration & dosage (417) 417
dosage and administration (412) 412
dermatology (410) 410
follow-up studies (407) 407
antimitotic agents (403) 403
retrospective studies (403) 403
disease-free survival (401) 401
internal medicine (401) 401
drug interactions (396) 396
protein kinase inhibitors - administration & dosage (394) 394
tyrosine kinase inhibitor (393) 393
drug therapy, combination (392) 392
hematology, oncology and palliative medicine (382) 382
rosuvastatin (372) 372
child (363) 363
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (363) 363
tumors (358) 358
triazoles - adverse effects (356) 356
toxicology (354) 354
double-blind (351) 351
trial (351) 351
antineoplastic agents - pharmacology (350) 350
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9418) 9418
Japanese (123) 123
German (105) 105
French (94) 94
Spanish (50) 50
Chinese (35) 35
Russian (26) 26
Italian (12) 12
Hungarian (10) 10
Danish (8) 8
Dutch (7) 7
Swedish (6) 6
Czech (5) 5
Polish (5) 5
Norwegian (4) 4
Portuguese (4) 4
Turkish (3) 3
Croatian (2) 2
Hebrew (2) 2
Finnish (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Frontiers of Medicine, ISSN 2095-0217, 4/2019, Volume 13, Issue 2, pp. 277 - 284
The development of new proton-pump inhibitors (PPIs) with less adverse effects by lowering the pKa values of nitrogen atoms in pyrimidine rings has been... 
pKa calculation | Medicine & Public Health | adverse effect | toxicological mechanism | pharmacological mechanism | Medicine/Public Health, general | proton-pump inhibitor | MEDICINE, RESEARCH & EXPERIMENTAL | OMEPRAZOLE | ENUMERATION | PREDICTION | DATABASE | ONCOLOGY | T3DB | PK(A) | Nitrogen | Pyrimidines | Medical research | Side effects | Inhibitor drugs
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2015, Volume 37, Issue 11, pp. 2449 - 2457
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2011, Volume 365, Issue 22, pp. 2078 - 2087
In this trial, intravascular ultrasonography was used to compare the effects of atorvastatin versus rosuvastatin on regression of coronary atherosclerosis.... 
MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | MYOCARDIAL-INFARCTION | CARDIOVASCULAR EVENTS | ATHEROSCLEROSIS | INTRAVASCULAR ULTRASOUND | RANDOMIZED CONTROLLED-TRIAL | AVERAGE CHOLESTEROL LEVELS | ROSUVASTATIN | ARTERY-DISEASE | ATORVASTATIN | Coronary Vessels - diagnostic imaging | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Ultrasonography, Interventional | Male | Heptanoic Acids - adverse effects | Coronary Artery Disease - pathology | Pyrroles - adverse effects | Cholesterol, LDL - blood | Female | Pyrroles - therapeutic use | Coronary Vessels - pathology | Double-Blind Method | Rosuvastatin Calcium | Coronary Artery Disease - drug therapy | Anticholesteremic Agents - adverse effects | Disease Progression | Atorvastatin Calcium | Coronary Artery Disease - diagnostic imaging | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Pyrimidines - adverse effects | Cholesterol, HDL - blood | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Fluorobenzenes - therapeutic use | Drugs | Rosuvastatin | Dosage and administration | Product/Service Evaluations | Drug therapy | Atherosclerosis | Lipoproteins (low density) | Clinical trials | Cardiovascular disease | Patients | Cholesterol | Studies | Side effects | Ultrasonic imaging | Arteriosclerosis | Ultrasonography | Atorvastatin | Heart diseases | Lipoproteins (high density) | Statins | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 09/2012, Volume 56, Issue 9, pp. 4793 - 4799
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 1019 - 1026
Summary Background Present first-line therapy for diffuse large B-cell lymphoma, a subtype of non-Hodgkin lymphoma, is rituximab, cyclophosphamide,... 
Hematology, Oncology and Palliative Medicine | THERAPY | OLDER PATIENTS | ONCOLOGY | FEBRILE NEUTROPENIA | PCI-32765 | CHRONIC LYMPHOCYTIC-LEUKEMIA | CLASSIFICATION | RANDOMIZED CONTROLLED-TRIAL | TARGETING BTK | ELDERLY-PATIENTS | CHEMOTHERAPY | Doxorubicin - therapeutic use | Pyrazoles - therapeutic use | Prognosis | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Dose-Response Relationship, Drug | Young Adult | Non-Randomized Controlled Trials as Topic | Aged, 80 and over | Adult | Female | Lymphoma, Non-Hodgkin - drug therapy | Pyrazoles - adverse effects | Severity of Illness Index | Antigens, CD20 - immunology | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Administration, Oral | Rituximab | Survival Rate | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Antigens, CD20 - drug effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Lymphoma, Non-Hodgkin - diagnosis | Care and treatment | Anthracyclines | Cyclophosphamide | Prednisone | Corticosteroids | Tumors | Index Medicus
Journal Article
BMJ : British Medical Journal, ISSN 0959-8138, 5/2013, Volume 346, Issue 7911, pp. 14 - 14
Objective To examine the risk of new onset diabetes among patients treated with different HMG-CoA reductase inhibitors (statins).Design Population based cohort... 
RESEARCH | Secondary prevention | Depopulation | Population growth | Diabetes | Older adults | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | THERAPY | EVENTS | CHOLESTEROL | CORONARY | DISEASE | PREVENTION | RANDOMIZED CONTROLLED-TRIAL | MELLITUS | ATORVASTATIN | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Simvastatin - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Male | Fluorobenzenes - administration & dosage | Heptanoic Acids - adverse effects | Diabetes Mellitus, Type 2 - epidemiology | Incidence | Dose-Response Relationship, Drug | Pyrroles - administration & dosage | Cardiovascular Diseases - epidemiology | Heptanoic Acids - administration & dosage | Pravastatin - adverse effects | Pyrroles - adverse effects | Diabetes Mellitus, Type 2 - etiology | Female | Retrospective Studies | Odds Ratio | Dyslipidemias - drug therapy | Pyrimidines - administration & dosage | Simvastatin - administration & dosage | Proportional Hazards Models | Rosuvastatin Calcium | Treatment Outcome | Atorvastatin Calcium | Dyslipidemias - epidemiology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Pravastatin - administration & dosage | Ontario - epidemiology | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Diabetes Mellitus, Type 2 - chemically induced | Population Surveillance | Sulfonamides - administration & dosage | Cohort Studies | Inhibitor drugs | Risk assessment | Statins | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article